Literatur
- 1
Acbay O, Gundogdu S.
Can metformin reduce
insulin resistance in polycystic ovary syndrome?.
Fertil
Steril.
1996;
65
946-949
- 2
Asuncion M, Calvo R M, San Millan J L, Sancho J, Avila S, Escobar-Morreale H F.
A
prospective study of the prevalence of the polycystic ovary syndrome
in unselected Caucasian women from Spain.
J Clin Endocrinol
Metab.
2000;
85
2434-2448
- 3
Azziz R, Ehrmann D, Legro R S, Whitcomb R W, Hanley R, Fereshetian A G, O’Keefe M,
Ghazzi M N.
Troglitazone
improves ovulation and hirsutism in the polycystic ovary syndrome:
a multicenter, double blind, placebo-controlled trial.
J
Clin Endocrinol Metab.
2001;
86
1626-1632
- 4
Batukan C, Baysal B.
Metformin improves ovulation
and pregnancy rates in patients with polycystic ovary syndrome.
Arch
Gynecol Obstet.
2001;
265
124-127
- 5
Cagnacci A, Arangino S, Renzi A, Cagnacci P, Volpe A.
Insulin
sensitivity in women: a comparison among values derived from intravenous glucose
tolerance tests with different sampling frequency, oral glucose
tolerance test or fasting.
Eur J Endocrinol.
2001;
145
281-287
- 6
Ciampelli M, Fulghesu A M, Cucinelli F, Pavone V, Ronsisvalle E, Guido M, Caruso A,
Lanzone A.
Impact of insulin and
body mass index on metabolic and endocrine variables in polycystic
ovary syndrome.
Metabolism.
1999;
48
167-172
- 7
Clayton R N, Ogden V, Hodgkinson J, Worswick L, Rodin D A, Dyer S, Meade T W.
How
common are polycystic ovaries in normal women and what is their
significance for the fertility of the population?.
Clin Endocrinol
(Oxf).
1992;
37
127-134
- 8
Crave J C, Fimbel S, Lejeune H, Cugnardey N, Dechaud H, Pugeat M.
Effects of diet and metformin
administration on sex hormone-binding globulin, androgens, and insulin
in hirsute and obese women.
J Clin Endocrinol Metab.
1995;
80
2057-2062
- 9
De Leo V, La Marca A, Orvieto R, Morgante G.
Effect of metformin on insulin-like
growth factor (IGF) I and IGF-binding protein I in polycystic ovary
syndrome.
J Clin Endocrinol Metab.
2000;
85
1598-1600
- 10
Dewailly D.
Definition
and significance of polycystic ovaries.
Baill Clin Obstet
Gynaecol.
1997;
11
349-368
- 11
Diamanti-Kandarakis E, Kouli C, Tsianateli T, Bergiele A.
Therapeutic effects
of metformin on insulin resistance and hyperandrogenism in polycystic
ovary syndrome.
Eur J Endocrinol.
1998;
138
269-74
- 12
Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I.
Increased endothelin-1
levels in women with polycystic ovary syndrome and the beneficial
effect of metformin therapy.
J Clin Endocrinol Metab.
2001;
86
4666-4673
- 13
Dunaif A.
Insulin
resistance and the polycystic ovary syndrome: mechanism and implications
for pathogenesis.
Endocr Rev.
1997;
18
774-800
- 14
Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J.
Prevalence of impaired glucose tolerance
and diabetes in women with polycystic ovary syndrome.
Diabetes
Care.
1999;
22
141-146
- 15
Ehrmann D A, Cavaghan M K, Imperial J, Sturis J, Rosenfield R L, Polonsky K S.
Effects of
metformin on insulin secretion, insulin action, and ovarian steroidogenesis
in women with polycystic ovary syndrome.
J Clin Endocrinol
Metab.
1997;
82
524-530
- 16
Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L.
Metformin-induced
resumption of normal menses in 39 of 43 (91 %)
previously amenorrheic women with the polycystic ovary syndrome.
Metabolism.
1999;
48
511-519
- 17
Glueck C J, Wang P, Fontaine R, Tracy T, Sieve-Smith L.
Metformin
to restore normal menses in oligo-amenorrheic teenage girls with
polycystic ovary syndrome (PCOS).
J Adolesc Health.
2001;
29
160-169
- 18
Hoeger K.
Obesity
and weight loss in polycystic ovary syndrome.
Obstet Gynecol
Clin North Am.
2001;
28
85-97
- 19
Huber-Buchholz M M, Carey D G, Norman R J.
Restoration of reproductive potential
by lifestyle modification in obese polycystic ovary syndrome: role
of insulin sensitivity and luteinizing hormone.
J Clin
Endocrinol Metab.
1999;
84
1470-1474
- 20
Ibanez L, Valls C, Potau N, Marcos M V, de Zegher F.
Sensitization
to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea,
dyslipidemia, and hyperinsulinism after precocious pubarche.
J
Clin Endocrinol Metab.
2000;
85
3526-3530
- 21
Ibanez L, Valls C, Ferrer A, Marcos M V, Rodriguez-Hierro F, de Zegher F.
Sensitization to insulin
induces ovulation in nonobese adolescents with anovulatory hyperandrogenism.
J
Clin Endocrinol Metab.
2001;
86
3595-3598
- 22
Jakubowicz D J, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H,
Koistinen R, Nestler J E.
Insulin
reduction with metformin increases luteal phase serum glycodelin
and insulin-like growth factor-binding protein 1 concentrations
and enhances uterine vascularity and blood flow in the polycystic
ovary syndrome.
J Clin Endocrinol Metab.
2001;
86
1126-1133
- 23
Kahsar-Miller M D, Nixon C, Boots L R, Go R C, Azziz R.
Prevalence of polycystic ovary syndrome
(PCOS) in first-degree relatives of patients with PCOS.
Fertil
Steril.
2001;
75
53-58
- 24
Knochenhauer E S, Key T J, Kahsar-Miller M, Waggoner W, Boots L R, Azziz R.
Prevalence
of the polycystic ovary syndrome in unselected black and white women
of the southeastern United States: a prospective study.
J
Clin Endocrinol Metab.
1998;
83
3078-3082
- 25
Koivunen R, Laatikainen T, Tomas C, Huhtaniemi I, Tapanainen J, Martikainen H.
The prevalence of
polycystic ovaries in healthy women.
Acta Obstet Gynecol
Scand.
1999;
78
137-141
- 26
Koivunen R M, Morin-Papunen L C, Ruokonen A, Tapanainen J S, Martikainen H K.
Ovarian steroidogenic response
to human chorionic gonadotrophin in obese women with polycystic
ovary syndrome: effect of metformin.
Hum Reprod.
2001;
16
2546-2551
- 27
Kolodziejczyk B, Duleba A J, Spaczynski R Z, Pawelczyk L.
Metformin therapy
decreases hyperandrogenism and hyperinsulinemia in women with polycystic
ovary syndrome.
Fertil Steril.
2000;
73
1149-1154
- 28
Kowalska I, Kinalski M, Straczkowski M, Wolczyski S, Kinalska I.
Insulin,
leptin, IGF-I and insulin-dependent protein concentrations after insulin-sensitizing
therapy in obese women with polycystic ovary syndrome.
Eur
J Endocrinol.
2001;
144
509-515
- 29
la Marca A, Morgante G, Paglia T, Ciotta L, Cianci A, De Leo V.
Effects of metformin
on adrenal steroidogenesis in women with polycystic ovary syndrome.
Fertil
Steril.
1999;
72
985-989
- 30
la Marca A, Egbe T O, Morgante G, Paglia T, Cianci A, De Leo V, Ciani A.
Metformin
treatment reduces ovarian cytochrome P-450c17alpha response to human
chorionic gonadotrophin in women with insulin resistance-related
polycystic ovary syndrome.
Hum Reprod.
2000;
15
21-23
- 31
Legro R S, Kunselman A R, Dodson W C, Dunaif A.
Prevalence
and predictors of risk for type 2 diabetes mellitus and impaired
glucose tolerance in polycystic ovary syndrome: a prospective, controlled
study in 254 affected women.
J Clin Endocrinol Metab.
1999;
84
165-169
- 32
Michelmore K F, Balen A H, Dunger D B, Vessey M P.
Polycystic
ovaries and associated clinical and biochemical features in young
women.
Clin Endocrinol (Oxf).
1999;
51
779-786
- 33
Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M.
Metformin effects on clinical
features, endocrine and metabolic profiles, and insulin sensitivity
in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled
6-month trial, followed by open, long-term clinical evaluation.
J
Clin Endocrinol Metab.
2000;
85
139-146
- 34
Morin-Papunen L C, Koivunen R M, Ruokonen A, Martikainen H K.
Metformin
therapy improves the menstrual pattern with minimal endocrine and
metabolic effects in women with polycystic ovary syndrome.
Fertil
Steril.
1998;
69
691-696
- 35
Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S.
Endocrine
and metabolic effects of metformin versus ethinyl estradiol-cyproterone
acetate in obese women with polycystic ovary syndrome: a randomized
study.
J Clin Endocrinol Metab.
2000;
85
3161-3168
- 36
Nestler J E, Jakubowicz D J.
Decreases
in ovarian cytochrome P450c17 alpha activity and serum free testosterone
after reduction of insulin secretion in polycystic ovary syndrome.
N
Engl J Med.
1996;
335
617-623
- 37
Nestler J E, Jakubowicz D J.
Lean women
with polycystic ovary syndrome respond to insulin reduction with
decreases in ovarian P450c17 alpha activity and serum androgens.
J
Clin Endocrinol Metab.
1997;
82
4075-4079
- 38
Nestler J E, Jakubowicz D J, Evans W S, Pasquali R.
Effects
of metformin on spontaneous and clomiphene-induced ovulation in
the polycystic ovary syndrome.
N Engl J Med.
1998;
338
1876-1880
- 39
Nestler J E, Stovall D, AkhterN, Iuorno M J, Jakubowicz D J.
Strategies for
the use of insulin-sensitizing drugs to treat infertility in women with
polycystic ovary syndrome.
Fert Steril.
2002;
77
209-215
- 40
Ng E H, Wat N M, Ho P C.
Effects
of metformin on ovulation rate, hormonal and metabolic profiles
in women with clomiphene-resistant polycystic ovaries: a randomized,
double-blinded placebo-controlled trial.
Hum Reprod.
2001;
16
1625-1631
- 41
Parsanezhad M E, Alborzi S, Zarei A, Dehbashi S, Omrani G.
Insulin
resistance in clomiphene responders and non-responders with polycystic
ovarian disease and therapeutic effects of metformin.
Int
J Gynaecol Obstet.
2001;
75
43-50
- 42
Pasquali R, Gambineri A, Biscotti D, Vicennati V, Gagliardi L, Colitta D, Fiorini S,
Cognigni G E, Filicori M, Morselli-Labate A M.
Effect
of long-term treatment with metformin added to hypocaloric diet
on body composition, fat distribution, and androgen and insulin
levels in abdominally obese women with and without the polycystic
ovary syndrome.
J Clin Endocrinol Metab.
2000;
85
2767-2774
- 43
Pirwany I R, Yates R W, Cameron I T, Fleming R.
Effects
of the insulin sensitizing drug metformin on ovarian function, follicular
growth and ovulation rate in obese women with oligomenorrhoea.
Hum
Reprod.
1999;
14
2963-2968
- 44
Unluhizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A.
The
effects of metformin on insulin resistance and ovarian steroidogenesis
in women with polycystic ovary syndrome.
Clin Endocrinol
(Oxf).
1999;
51
231-236
- 45
Vandermolen D T, Ratts V S, Evans W S, Stovall D W, Kauma S W, Nestler J E.
Metformin
increases the ovulatory rate and pregnancy rate from clomiphene
citrate in patients with polycystic ovary syndrome who are resistant
to clomiphene citrate alone.
Fertil Steril.
2001;
75
310-315
- 46
Velazquez E M, Mendoza S, Hamer T, Sosa F, G lueck C J.
Metformin therapy
in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance,
hyperandrogenemia, and systolic blood pressure, while facilitating
normal menses and pregnancy.
Metabolism.
1994;
43
647-654
- 47
Velazquez E, Acosta A, Mendoza S G.
Menstrual
cyclicity after metformin therapy in polycystic ovary syndrome.
bstet
Gynecol.
1997;
90
392-395
- 48
Velazquez E M, Mendoza S G, Wang P, Glueck C J.
Metformin therapy
is associated with a decrease in plasma plasminogen activator inhibitor-1,lipoprotein(a),
and immunoreactive insulin levels in patients with the polycystic
ovary syndrome.
Metabolism.
1997;
46
454-457
- 49
Vrbikova J, Hill M, Starka L, Cibula D, Bendlova B, Vondra K, Sulcova J, Snajderova M.
The effects of long-term
metformin treatment on adrenal and ovarian steroidogenesis in women
with polycystic ovary syndrome.
Eur J Endocrinol.
2001;
144
619-628
- 50
Wild S, Pierpoint T, McKeigue P, Jacobs H.
Cardiovascular disease
in women with polycystic ovary syndrome at long-term follow-up:
a retrospective cohort study.
Clin Endocrinol (Oxf).
2000;
52
595-600
Dr. med. Christoph J. Auernhammer
Medizinische Klinik II, Klinikum der Ludwig-Maximilians-Universität, Standort
Grosshadern
Marchioninistr. 15
81377 München
Phone: +49/89/70950
Fax: +49/89/7004418
Email: Christoph.Auernhammer@med2.med.uni-muenchen.de
